Novartis unveils promising interim Phase 2 data for iptacopan in C3G
Novartis has unveiled positive data for its investigational oral treatment iptacopan from interim analysis of a Phase 2 study evaluating C3 glomerulopathy (C3G) patients who have undergone kidney